Long-term effects of rotational atherectomy in patients with heavy calcified coronary artery lesions : a single-centre experience by Bartuś, Stanisław et al.
www.kardiologiapolska.pl
Kardiologia Polska 2017; 75, 6: 564–572; DOI: 10.5603/KP.a2017.0042
ARTYKUŁ ORYGINALNY / ORIGINAL ARTICLE
Address for correspondence:  
Rafał Januszek, MD, PhD, 2nd Department of Cardiology and Cardiovascular Interventions, University Hospital, ul. Kopernika 17, 31–501 Kraków, Poland,  
e-mail: jaanraf@interia.pl
Received: 25.10.2016 Accepted: 07.02.2017 Available as AoP: 07.03.2017
Kardiologia Polska Copyright © Polskie Towarzystwo Kardiologiczne 2017
Long-term effects of rotational atherectomy  
in patients with heavy calcified coronary  
artery lesions: a single-centre experience
Stanisław Bartuś1, 2, Rafał Januszek1, Jacek Legutko1, 2, Łukasz Rzeszutko1,  
Artur Dziewierz1, 2, Dariusz Dudek1, 2, 3
12nd Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland
22nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland 
3Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland 
A b s t r a c t
Background: Rotational atherectomy (RA) plays a significant role in contemporary percutaneous coronary interventions (PCI), 
especially in the era of population aging and expansion of PCI indications. 
Aim: The aim of the current study was to evaluate the rate of periprocedural complications, the long-term effectiveness of 
RA, and potential factors influencing the incidence of major adverse cardiac events (MACE) and major cardiac as well as 
cerebrovascular events (MACCE) after RA. 
Methods: The study included 60 consecutive patients who underwent effective RA between January 2002 and May 2016. Pa-
tients were followed-up for 2,616 days for MACE and MACCE.
Results: The mean age of the enrolled patients was 72.1 years, and 78.3% were males. The mean follow-up period lasted 
835.3 ± 611.8 days. Periprocedural complications occurred in 12 (20.0%) patients. In the follow-up of up to 2,616 days, 64% 
of patients were free of MACCE and 68% were free of MACE. Univariate Cox analysis revealed that MACCE occurred more 
often in patients from the high-risk group based on the EuroSCORE II and those with longer lengths of the implanted stent(s) 
after the RA procedure. In multivariate Cox regression analysis, both high-risk category and mean stent(s) length were identified 
as independent predictors of MACCE. EuroSCORE II was confirmed to be the only independent predictor of MACE after RA.
Conclusions: Rotational atherectomy is a safe and sufficient technique for the endovascular treatment of heavily calcified 
coronary artery lesions. Individuals at a higher risk as assessed by the EuroSCORE II before RA and those with longer stent(s) 
implanted after RA are predisposed to MACCE in the follow-up.
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INTRODUCTION
Next year will mark the 30th anniversary since Jerome Ritchie, 
David Auth and colleagues introduced rotational atherec-
tomy (RA) as a technique for endovascular treatment [1]. 
RA, alongside orbital atherectomy (OA) and excimer laser 
(EL) atherectomy, belongs to the world’s leading techniques 
used for the atherectomy of calcified coronary artery lesion 
(CCAL). Recent estimates indicate that the current frequency 
of RA use has trended downward in the last several years, 
especially in low-volume centres. In European countries, 
the rate of RA ranges from 0.8% to 3.1% of all percutaneous 
coronary interventions (PCIs) [2]. The crucial advantage of RA 
over regular PCI is the enlargement of the artery lumen by 
physical removal of plaque and reduction in plaque rigidity, 
which enables easier dilation of the artery. Vascular stiffness 
is mainly determined by coronary artery calcification (CAC). 
The core of the RA device is a diamond-encrusted elliptical 
burr, which is rotated at high speeds. The procedural success 
of RA with subsequent coronary stenting reaches more than 
90% [3]. In the past, when balloon angioplasty and stents were 
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used to treat severe CCALs, the major adverse cardiac event 
(MACE) rate ranged from 11% to 15.8% at 15 months [4]. 
The rate of MACE in patients after RA and coronary stenting 
with drug-eluting stent (DES) was lower in comparison to the 
MACE rates reported in DES alone PCIs trials that have as-
sessed the PCI of moderate and severely calcified lesions [5]. 
Recently published intermediate and long-term outcomes 
after PCI and DES with adjunctive RA report rates of target 
lesion revascularisation (TLR) < 10% within one to two years 
[6]. In patients treated with RA, rates of MACE are lower with 
DES stenting compared with bare-metal stent (BMS) stenting 
[6, 7]. However, the ROTAXUS study did not demonstrate 
the advantage of RA with DES implantation over angioplasty 
with DES alone [8]. The number of published studies with 
long-term follow-ups is small and limited to randomised 
controlled trials. Therefore, smaller single-centre studies with 
long-term follow-ups may bring additional insight into the 
effectiveness of RA in patients with CCAs.
The aim of this study was to assess the effectiveness, 
periprocedural complications, and long-term effects of RA in 
terms of MACEs and major adverse cardiac and cerebrovas-
cular events (MACCEs) in patients with heavy CCAs.
METHODS
Data on 60 consecutive patients who underwent effective 
RA in our centre between January 2002 and May 2016 were 
collected, retrospectively. However, most procedures were 
performed in the past five years (55 rotablations; 91.6%). The 
maximum follow-up time was 2,616 days. The patient evalu-
ation was based on both clinical interview and an additional 
non-invasive evaluation of cardiac ischaemia when possible. 
The pre-procedure clinical risk was defined according to the 
additive EuroSCORE II and SYNTAX score calculator, and 
was defined as low risk (≤ 2%), intermediate risk (3–5%), 
and high risk (≥ 6%), considering the EuroSCORE II and as 
low (0–22 points), intermediate (23–32 points), and high 
(≥ 33 points) when considering the SYNTAX score.
A Rotablator (Boston Scientific, Marlborough, MA, 
USA) was used to perform RA. As recommended, patients 
with absolute contraindications to RA, i.e. saphenous vein 
graft lesions, thrombus, dissection, and occlusions through 
which a guidewire would not pass, were excluded. Relative 
contraindications including indication to bypass surgery (not 
possible to perform whether due to patient ineligibility or lack 
of on-site cardiac surgery), severe three-vessel or unprotected 
left main disease, severe left ventricular dysfunction, lesion 
length more than 25 mm, and lesion angulation more than 
45 degrees were assessed individually, and the final decision 
was made by the main operator of the procedure. All patients 
gave informed consent for the procedure. The study complies 
with the Declaration of Helsinki on the ethical principles for 
medical research involving human subjects. 
Primary study endpoints
The study endpoints were the rates of MACE and MACCE 
defined as cardiac death, myocardial infarction (MI), the 
requirement of TLR for MACE, and cardiac death, MI, 
the requirement of TLR, and cerebral stroke for MACCE. 
Death was considered to be of cardiac origin unless obvious 
non-cardiac causes could be identified. TLR was defined as 
either PCI — plain old balloon angioplasty (POBA)/DES or 
coronary artery bypass grafting (CABG) performed to treat 
in-stent restenosis or stent thrombosis of the target lesion, 
including the proximal and distal edges of the stent. 
Secondary study endpoints 
The secondary endpoints included angiographic success 
defined as success in facilitating stent delivery with a residual 
stenosis < 50%, without severe angiographic complications 
as well as the rate of individual severe angiographic complica-
tions during the procedure. Severe angiographic complications 
included severe dissections, perforation, persistent slow-flow, 
persistent no-reflow, and abrupt closure. Periprocedural com-
plications included time from the procedure to the discharge 
of the patient. 
Statistical analysis
The Kaplan-Meier analysis method was used for the primary 
endpoint assessment. Descriptive statistics are provided for 
secondary endpoints. The data are expressed as means with 
standard deviations (SD) and percentage distribution as ap-
propriate. Both univariate and multivariate Cox proportional 
hazards model analyses for MACE and MACCE were per-
formed. Statistical significance was accepted at a 0.05 level 
of probability. The statistical analyses were performed using 
Statistica 10.0 software (Dell Software, Inc., Round Rock, 
TX, USA). 
RESULTS
Baseline clinical characteristics are presented in Table 1. In 
terms of risk stratification (EuroSCORE II), a total of 38.3% 
patients were in the low-risk group, 41.7% in the moder-
ate-risk group, and 20% had a EuroSCORE ≥ 6%. The mean 
SYNTAX score was 24.6 ± 13.6 points. A total of 43.3% of 
patients had a SYNTAX score < 22 points, 28.3% between 
22 and 32 points, and 28.3% of patients had a SYNTAX 
score ≥ 33 points. All patients were treated with dual anti-
platelet therapy after RA. All patients received aspirin, and as 
the second antiplatelet agent, clopidogrel was prescribed for 
54 patients, prasugrel or ticagrelor in five patients, and one 
patient was treated with ticlopidine. Other medical treatment 
was continued in accordance with the current cardiologic 
guidelines and existing comorbidities. The main direct indi-
cation for RA was the inability to push the balloon catheter 
through the stenosis (69.5%). However, only in a few cases, 
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an over-the-wire catheter was used for such attempts. For 
patients in whom an over-the-wire catheter was used to 
deliver the balloon catheter, the attempt to deliver balloon 
catheter was effective in 80% of cases. In 25.4% of patients, 
successful delivery of balloon catheter was achieved, while 
satisfactory dilatation of the calcified artery was not sufficient 
or impossible. The acceptable predilatation was not possible, 
despite the use of high-pressure and/or cutting balloons in 
nearly 40% of patients out of those with unsuccessful predila-
tation. Finally, despite considering satisfactory predilatation, 
stent delivery failed in 5.1% of cases. The type and number 
of arteries that were treated with RA are presented in Table 2. 
A Floppy Rotawire was used in 58.3% of cases, whereas an 
Extra Support Rotawire was used in 41.7% of cases. In patients 
in whom the operator decided that coronary arteries were 
tortuous, the first choice was Floppy Rotawire, while in the 
remaining cases, an Extra Support Rotawire was used. The 
RA was conducted with pecking movements at a speed of 
approx. 150,000 rotations per minute. Every time we ran RA, 
we performed a few pecking movements. This action was 
repeated until achieving effortless burr passage to the distal 
part of the artery. Usually, a dozen to several dozen pecking 
movements were sufficient to achieve the intended purpose. 
In three cases, PCI after RA was performed without stent im-
plantation — POBA (5%), and in another two patients, BMS 
was implanted (3.33%), whereas other patients underwent 
DES placement. The mean stent length was 25.1 ± 8.7 mm 
and the diameter was 3.1 ± 0.4 mm. Twenty-nine (48.3%) 
patients underwent single-stent implantation, 21 (35%) 
double-stent implantation, six (10%) triple-stent implantation, 
and one (1.7%) quadruple-stent implantation. The relation-
ship between final maximum burr diameter, final maximum 
balloon diameter, and final maximum stent diameter is 
presented in Figure 1. The right common femoral artery was 
most often used for vascular access (72%). The radial artery 
access was found in 18% of procedures and was featured in 
the most recent PCIs. Elective operations accounted for the 
majority of procedures at 46.7%, followed by urgent 28.3%, 
emergency 21.7%, and salvage procedures in 3.3%. Stable 
angina was the most common clinical presentation in pa-
tients qualified for RA (46.7%), followed by unstable angina 
(31.7%), non-ST-segment elevation MI (NSTEMI) (18.3%), and 
ST-segment elevation MI (STEMI) (3.3%). The type of culprit 
lesion according to the ACC/AHA guidelines was 2B in 21.7% 
Table 1. General patients’ characteristics
Overall group n = 60
Male/Female 47/13 
Age [years] 72.2 ± 9.5
Body mass index [kg/m2] 28.8 ± 5.3
EurosCORE II [%] 6.5 ± 13
GFR [mL/min] 71.8 ± 29.1 
Left ventricular ejection fraction [%] 46.6 ± 11.9 
Past and current smokers 47 (78.3%) 
Peripheral artery disease 16 (26.7%) 
Previous MI 41 (68.3%)
Previous PCI 42 (70.0%)
Previous CABG 11 (18.3%)
Hypertension 58 (96.7%)
Diabetes 30 (50.0%)
Insulin therapy 14 (23.3%)
Dyslipidaemia 57 (95.0%)
Obesity 16 (26.7%)
COPD/bronchial asthma 10 (16.7%)
Atrial fibrillation 18 (30.0%)
Chronic kidney disease 15 (25.0%)
Cerebral stroke/TIA 9 (15.0%)
Values are expressed as mean ± standard deviation and percentage 
distribution. CABG — coronary artery bypass grafting; COPD — chronic 
obstructive pulmonary disease; GFR — glomerular filtration rate;  
MI — myocardial infarction; PCI — percutaneous coronary interven-
tion; TIA — transient ischaemic attack
Table 2. Localisation of atherosclerotic lesions (significant 
stenoses/occlusions) in coronary arteries
Arteries subjected to PCI: n Location Cases: n (%)
Total number, 79 RCA 16 (20.2%)
LMCA 13 (16.4%)
LAD 26 (32.9%)
Cx 17 (21.5%)
Mg 3 (3.8%)
Dg 4 (5%)
The types of lesion
single artery/branch, 44 (73.3%) RCA 16 (36.4%)
LMCA 1 (2.3%)
LAD 14 (31.8%)
Cx 10 (22.7%)
Mg 2 (4.5%)
Dg 1 (2.3%)
Two arteries/branches, 13 (21.7%) LMCA-LAD 7 (53.8%)
LMCA-Cx 2 (15.4%)
LAD-Dg 2 (15.4%)
Dg-Cx 1 (7.7%)
LAD-Cx 1 (7.7%)
Three arteries/branches, 3 (5%) LMCA-LAD-Cx 3 (100%)
Values are expressed as percentage distribution. Cx — circumflex  
artery; Dg — diagonal artery; LAD — left anterior descending artery; 
LMCA — left main coronary artery; Mg — marginal artery;  
RCA — right coronary artery
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of cases and C in 78.3%. PCI was assisted with an intravascular 
ultrasound device (Eagle Eye® Platinum Catheter, Volcano) in 
15 (25%) patients and with optical coherence tomography 
in two (3.3%) patients. A single 1.25-mm burr was used in 
12 (20%) patients, 1.5-mm in 32 (53.3%), 1.75-mm in eight 
(13.3%), 2.0-mm in three (5%) patients, and 2.5-mm in one 
(1.7%) patient. In two (3.3%) cases, a 1.25-mm burr size was 
used initially with progression to a 1.5-mm burr. In one case, 
it was necessary to replace the primary 1.25-mm burr with 
a 1.75-mm burr (1.7%), and in another one, the primary 
1.25-mm burr was replaced with a 1.5-mm, and finally with 
a 1.75-mm burr, which led to successful RA (1.7%). The mean 
burr size was 1.53 ± 0.23 mm. The mean contrast volume 
used for the procedure including coronary angiography prior 
to the procedure was 283.6 ± 106.6 mL, and mean radia-
tion exposure was revealed at 2.16 ± 1.16 Gy. We noticed 
periprocedural complications in 12 (20%) patients. Among 
them, coronary artery dissection occurred in one patient, 
cardiogenic shock followed by death in two patients, car-
diogenic shock with hypotonia demanding inotropes and 
vasopressors in one patient, periprocedural MI in two cases, 
local haematoma demanding blood transfusion in one case, 
guidewire cutting and pericardial contrast extravasation in 
one case, slow-flow phenomenon and bradycardia in one 
case, contrast nephropathy in one patient, perforation of 
femoral artery with extraperitoneal haematoma demanding 
surgical supply in one case, and supraventricular tachycardia 
treated with intravenous antiarrhythmic drugs in one case. 
The relationship between ischaemic complications during 
the RA procedure and clinical presentation of coronary artery 
disease is demonstrated in Table 3. Based on retrospective 
observations, slow-flow and no-reflow phenomenon tend to 
occur after RA in patients with acute coronary syndromes, 
especially STEMI, where the risk soft thrombotic lesions is 
substantially higher. The risk of embolisation of the peripheral Ta
bl
e 
3.
 T
he
 r
el
at
io
ns
hi
p 
be
tw
ee
n 
cl
in
ic
al
 p
re
se
nt
at
io
n 
of
 c
or
on
ar
y 
ar
te
ry
 d
is
ea
se
 a
nd
 is
ch
ae
m
ic
 c
om
pl
ic
at
io
ns
 in
 p
at
ie
nt
s 
un
de
rg
oi
ng
 r
ot
at
io
na
l a
th
er
ec
to
m
y.
C
lin
ic
al
 p
re
se
n
ta
ti
o
n
  
o
f 
C
A
D
 b
ef
o
re
 R
A
N
u
m
b
er
  
o
f 
p
at
ie
n
ts
  
N
 (
%
)
M
ea
n
 L
V
EF
 
M
ea
n
 ±
 S
D
N
ew
 IL
V
M
 —
 
m
o
ti
o
n
  a
b
n
o
rm
al
it
ie
s 
af
te
r 
RA
  
N
 (
%
)
Tr
o
p
o
n
in
 
in
cr
ea
se
 
af
te
r 
RA
 
N
 (
%
)
N
ew
 is
ch
ae
m
ic
 
p
at
te
rn
s 
in
 E
C
G
 
af
te
r 
RA
C
o
m
p
lic
at
io
n
s
Tr
an
si
en
t 
 
tr
o
p
o
n
in
 
in
cr
ea
se
  
N
 (
%
)
Pe
ri
p
ro
ce
d
u
ra
l 
M
I  
N
 (
%
)
Sl
o
w
-fl
o
w
 o
r 
n
o
-fl
o
w
  
p
h
en
o
m
en
o
n
  
N
 (
%
)
D
ea
th
  
N
 (
%
)
st
ab
le
 a
ng
in
a
28
 (4
6.
6%
)
49
.7
 ±
 1
2.
2
2 
(7
.1
%
)
8 
(2
8.
6%
)
2
6 
(2
1.
4%
)
2 
(7
.1
%
)
0 
0
U
ns
ta
bl
e 
an
gi
na
19
 (3
1.
6%
)
43
.8
 ±
 1
0.
8
0
5 
(2
6.
3%
)
0
5 
(2
6.
3%
)
0
0
1 
(5
.2
%
)
N
sT
EM
I
11
 (1
8.
3%
)
44
.4
 ±
 1
3.
1
N
A
3 
(2
7.
2%
)
0
3 
(2
7.
2%
)
0
0
0
sT
EM
I
2 
(3
.3
%
)
45
 ±
 7
.0
7
N
A
N
A
N
A
N
A
N
A
1 
(5
0%
)
1 
(5
0%
)
CA
D
 —
 c
or
on
ar
y 
ar
te
ry
 d
is
ea
se
; E
CG
 —
 e
le
ct
ro
ca
rd
io
gr
am
; I
LV
W
 —
 is
ch
ae
m
ic
 le
ft
 v
en
tr
ic
ul
ar
 w
al
l; 
LV
EF
 —
 le
ft
 v
en
tr
ic
ul
ar
 e
je
ct
io
n 
fr
ac
tio
n;
 M
I —
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 N
sT
EM
I —
 n
on
-s
T-
se
gm
en
t 
el
ev
at
io
n 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 R
A
 —
 r
ot
at
io
na
l a
th
er
ec
to
m
y;
 s
D
 —
 s
ta
nd
ar
d 
de
vi
at
io
n;
 s
TE
M
I —
 s
T-
se
gm
en
t 
el
ev
at
io
n 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 N
A
 —
 n
ot
 a
de
qu
at
eFigure 1. The relationship between final maximum burr dia-
meter, final maximum balloon diameter used after rotablation, 
and final maximum diameter of implanted stent
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arteries in patients with stable angina and potentially more 
dense embolic material seems to be firmly lower. 
Follow-ups were conducted in 50 (83.3%) patients after 
the RA. The Kaplan-Maier curve revealed 64% patients free of 
MACCE and 68% free of MACE after the maximal 2,616 days 
of observation (Fig. 2). The mean time of the follow-up pe-
riod was 835.3 ± 611.8 days. During follow-up, there were 
six deaths, including two periprocedural deaths, eight TLRs, 
four cerebral strokes, and four MIs. Univariate Cox analysis 
revealed that MACCE occurred significantly more often in 
patients from the high-risk group assessed before the RA by 
the EuroSCORE II (Table 4). Also, longer length of the im-
planted stent(s) after the RA procedure was related to lower 
MACCE occurrence (Table 4). In multivariate Cox regression 
analysis, both high-risk category based on EuroSCORE II (HR 
5.53; 95% CI 1.78–17.23; p = 0.003) and mean stent(s) 
length (HR [95% CI] high-risk vs. other: 0.89 [0.81–0.98]; 
p = 0.013) were identified as independent predictors of 
MACCE. Similarly, EuroSCORE II was confirmed to be the 
only independent predictor of MACE after RA (HR [95% CI] 
per 1%: 1.08 [1.03–1.13]; p < 0.001).
DISCUSSION
In the current study, all RA procedures were effective from 
the technical side and were completed with successful PCI. 
However, this did not allow avoidance of severe complica-
tions, such as the death of the patient in two cases. Almost 
90% of RAs were performed with 1.25- and 1.5-mm single 
burr passages. This confirms the presently observed trends 
that usually, a few passages with single burr diameter (most 
often 1.5 mm in diameter) are sufficient to continue success-
ful PCI with stent implantation [2]. It is suggested that a single 
1.5-mm burr represents a good compromise when tackling 
different lesion characteristics and achieves good plaque 
modification. A different strategy is the burr-to-artery ratio of 
0.6. It is justified especially when considering budget con-
straints. However, a step-up approach starting with a 1.25-mm 
burr up to a 1.5-mm and to a 1.75-mm burr is deemed by 
experts to be a safer approach [2]. Although, this approach is 
more expensive. High rotational speeds facilitate longitudinal 
burr movement across calcific lesions [2]. The most common 
complications of RA are similar to those that can be observed 
in patients after regular PCI, and they include vascular access 
complications, stroke, MI, urgent CABG, and death. In the 
current study, severe local bleeding from the artery puncture 
site occurred in one patient. The rise in the frequency of 
radial artery access in the present study remains in line with 
international trends and is determined by relatively safe access 
of 6 and 7 French sheaths for 1.25- and 1.5-mm burr sizes. An-
giographic complications include artery dissection, perfora-
tion, short-term closure, side branch loss, and the slow-flow 
or no-reflow phenomenon [2]. Complications, especially 
attributed to RA, include vasospasm and burr entrapment. 
Plaque modification during RA decreases the likelihood of 
procedural failure, stent under-deployment, restenosis, and 
major complications. Retrospective studies present high rates 
of short-term procedural success in patients undergoing RA. 
They range from 93.4% to 98.6% and do not deviate from 
our results. For example, Moussa et al. [3] reported proce-
dural success in 93.4% of individuals. Periprocedural success 
rates are superior in patients with RA compared to those re-
ported separately in the absence of plaque modification. 
Coronary lesions with CAC are classified as complex lesions 
and carry lower success rates and higher complication rates 
Figure 2. The Kaplan-Maier curves of major adverse cardiovascular events (MACE) (A) and cardiovascular and cerebrovascular 
events (MACCE) (B)
A B
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following PCI than do non-calcified or mildly calcified lesions 
[5, 9]. In the current study, the percentage of complex lesions 
with advanced calcifications was high (78.3% of type C and 
21.7% of type B) and comparable with other studies. Ad-
vanced CAC also poses technical challenges during PCI result-
ing in stent under-expansion, malposition, or the inability to 
place a stent [8]. Extensive CAC may damage the polymer 
coating of DES and contribute to decreased DES effectiveness 
[10]. Treatment of challenging calcified lesions often leads to 
increased MACE rates. The ORBIT II trial reported the suc-
cessful stent delivery in 97.7% of the included patients and 
residual stenosis < 50% in 98.6% with a low angiographic 
complication rate [11, 12]. The incidence of slow-flow and 
no-reflow was notably very low, occurring in < 1% of pa-
tients. In contrast, Japanese studies on RA show a range of 
0% to 18% [13]. In our study, we also noticed one patient 
with the slow-flow phenomenon. In previously published 
studies, the percentage of advanced dissections have ranged 
from 2.1% to 8.4% [14]. We observed one coronary artery 
dissection and one coronary artery perforation due to guide-
wire cutting. Perforation rates of 0% to 1.5% have been re-
ported with high-speed RA, and they differ based on tech-
nique [15]. The ORBIT II trial had among the lowest rates of 
this complication [11]. Similarly, abrupt closure occurred in 
Table 4. Univariate analysis of factors influencing the incidence of major adverse cardiac events (MACE) and major cardiac and 
cerebrovascular events (MACCE) after rotational atherectomy procedure
MACCE — HR (95% CI) P MACE — HR (95% CI) P
Gender (male/female) 0.58 (0.22–1.54) 0.28 0.66 (0.23–1.91) 0.45
Access (femoral/radial) 0.78 (0.22–2.76) 0.70 0.64 (0.18–2.34) 0.50
IVUs control (yes/no) 0.83 (0.28–2.54) 0.75 0.99 (0.32–3.07) 0.99
Past CABG (yes/no) 2.40 (0.90, 6.42) 0.08 1.51 (0.49–4.68) 0.48
Past PCI (yes/no) 0.59 (0.23–1.51) 0.27 0.65 (0.24–1.79) 0.41
Diabetes mellitus (yes/no) 1.55 (0.60–4.00) 0.37 1.67 (0.61–4.60) 0.32
Insulinotherapy (yes/no) 2.0 (0.78–5.16) 0.15 1.90 (0.69–5.23) 0.21
Peripheral arterial disease (yes/no) 1.02 (0.36–2.86) 0.97 1.21 (0.42–3.49) 0.72
Cerebral stroke/TIA (yes/no) 0.89 (0.26–3.07) 0.85 1.05 (0.30–3.67) 0.95
Atrial fibrillation (yes/no) 1.71 (0.67–4.34) 0.26 1.60 (0.59–4.29) 0.35
COPD (yes/no) 0.56 (0.13–2.44) 0.44 0.65 (0.15–2.86) 0.57
Heart failure (yes/no) 0.81 (0.30–2.15) 0.67 0.75 (0.26–2.17) 0.60
Antiplatelet therapy (DAPT and OAC vs. DAPT) 1.73 (0.67–4.48) 0.26 1.55 (0.56–4.28) 0.40
Age (per 10 years) 0.99 (0.60–1.63) 0.96 0.93 (0.55–1.57) 0.78
Mean stent diameter (per 1 mm) 1.16 (0.53–2.56) 0.72 1.04 (0.45–2.41) 0.94
Mean stent length (per 1 mm) 0.92 (0.86–0.99) 0.034 0.94 (0.87–1.01) 0.09
Maximal burr size (per 1 mm) 1.71 (0.50–5.92) 0.40 5.24 (0.69–39.73) 0.11
Contrast volume (per 100 mL) 1.44 (0.93–2.23) 0.10 1.52 (0.98–2.35) 0.06
LVEF (per 1%) 1.00 (0.96–1.05) 0.92 1.00 (0.95–1.04) 0.80
Radiation dose (per 1 Gy) 1.39 (0.95–2.03) 0.09 1.50 (1.01–2.21) 0.043
serum creatinine level (per 10 µmol/L) 1.08 (0.98–1.19) 0.13 1.08 (0.98–1.19) 0.12
GFR (per 1 mL/min) 0.99 (0.97–1.01) 0.41 0.99 (0.97–1.01) 0.53
syNTAx score (per 1 point) 1.03 (1.00–1.07) 0.10 1.03 (0.99–1.06) 0.18
EurosCORE II (per 1%) 1.09 (1.04–1.15) < 0.001 1.08 (1.03–1.13) < 0.001
Rotablated artery (RCA/other) 0.28 (0.06–1.22) 0.09 0.33 (0.08–1.45) 0.14
Number of stents (per 1 stent) 0.99 (0.53–1.85) 0.98 1.13 (0.60–2.11) 0.71
Procedure mode (elective vs. other) 0.52 (0.19–1.37) 0.18 0.48 (0.17–1.39) 0.18
Risk group according to syNTAx score (high risk vs. other) 1.07 (0.40–2.85) 0.90 0.95 (0.33–2.72) 0.92
Risk group according to EurosCORE II (high risk vs. other) 2.66 (1.03–6.89) 0.044 2.34 (0.85–6.44) 0.10
CABG — coronary artery bypass grafting; CI — confidence interval; COPD — chronic obstructive pulmonary disease; DAPT — dual antiplatelet  
therapy; GFR — glomerular filtration rate; HR — hazard ratio; IVUs — intravascular ultrasound; LVEF — left ventricular ejection fraction; OAC — 
oral anticoagulation; PCI — percutaneous coronary intervention; RCA — right coronary artery; TIA — transient ischaemic attack
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0.9% of individuals after the use of OA, and in 1.8%, after 
the procedure, compared with rates from 1% to 4% from 
other studies that reported abrupt closure during RA [11, 12]. 
Perforations occurred in 0.9% of patients after the use of OA 
and in 1.8% after the procedure, compared with 0.4% to 
2.5% in RA studies reporting on this complication [15]. The 
perforation rate after OA use is in the low end of the previ-
ously reported range, and the final ORBIT II perforation rate 
is within the range. Despite these successes, other reports 
suggest that distal embolisation of atherectomy fragments may 
result in slow-flow or no-reflow, which can result in serious 
complications such as adverse ischaemic and clinical events 
including, but not limited to, microvascular spasm, MI, and 
no-reflow phenomenon [16, 17]. RA has been proven to be 
superior to other atherectomy devices with respect to plaque 
modification. In the ERBAC study, RA had the greatest initial 
success percentage: 89% vs. 77% in the EL group and vs. 80% 
in balloon angioplasty (BA) group. No differences were ob-
served regarding major in-hospital complications and after six 
months [18]. TLR was performed more frequently in the RA 
group (42.4%) and the EL group (46.0%) than in the BA group 
(31.9%, p = 0.013) [18]. In the COBRA trial, 502 patients 
were enrolled and similar results were achieved [19]. The 
procedural success was achieved in 78% of individuals from 
the PCI group, and in 85% of the RA group (p = 0.038). There 
was no difference between PCI and RA in periprocedural 
complications including Q-wave infarctions (2.4% each), 
emergency CABG (1.2% and 2.4%), and death (1.6% and 
0.4%). However, more stents were required after regular PCI 
in comparison to PCI with RA. The procedural success rates 
after inclusion of the bail-out stents were 73% for angio-
plasty and 84% for RA (p = 0.006). After six months of fol-
low-ups, the symptomatic outcome, TLR, and in-stent reste-
nosis were not statistically different in the PCI group (51%) or 
RA group (49%) [20]. Most published studies demonstrate 
better long-term effects of RA with DES than DES alone in 
terms of MACE and MACCE. The ROTAXUS survey included 
240 patients with moderately or severely calcified obstructive 
lesions treated with or without RA before paclitaxel-eluting 
stent implantation and brought about different conclusions 
[8]. Greater strategic success and short-term lumen gain were 
noticed in the RA group. However, angiographic follow-up 
at nine months showed no difference in MACE and greater 
late lumen loss. In the ROTAXUS study, the MACE rate for 
calcified lesions treated with RA and DES was approximately 
24% at nine months. In the current study, relatively high 
procedural and 30-day MACE rate were determined mainly 
by two deaths during the RA procedure. It is noteworthy that 
those two deaths occurred in extremely high-risk patients who 
were qualified for angioplasty as a salvage procedure. The 
first patient underwent RA of the left main coronary artery 
(LMCA) and additionally suffered from severe aortic steno-
sis. Moreover, this patient’s EuroSCORE II value of was 56% 
and SYNTAX score was 45 points. Parallel to RA, balloon 
aortic valvuloplasty was performed. The second patient un-
derwent RA of the left anterior descending artery, which was 
additionally occluded by a thrombus, with STEMI and salvage 
mode, his EuroSCORE II value was 74.7% and SYNTAX score 
was 30.5 points. The RA procedure was performed in this 
patient despite the presence of contraindication — throm-
bus. However, after thrombectomy, it was not possible to 
perform effective PCI or deliver the stent due to advanced 
CAC. PCI using RA for LMCA lesions was reported to be 
feasible despite the high hospital mortality rate (7.5%), which 
is comparable to that seen in our study [20]. In the present 
study, the in-hospital mortality rate was 3.8% and the 30-day 
mortality rate was 3.8%. Patients with severe CCAL are at very 
high risk and have poor prognosis in the short- and medi-
um-term follow-up. In the current study, the cardiac mortal-
ity rate the one-year of follow-up was 5.7%, which is consid-
ered acceptable because our study population had severely 
calcified lesions, high SYNTAX scores, and high Euro-
SCOREs. The flattening of MACE and MACCE curves after 
four years of follow-ups is due to a decrease in the number 
of patients who have reached such a long observational pe-
riod. Undoubtedly, this causes underestimation of the rate of 
MACE and MACCE in more distant years of follow-up. Pro-
vided that well-trained operators are available, RA may be 
used as a device of choice, even in less experienced low-vol-
ume centres. Additionally, stent technology has improved and 
it is difficult to estimate the influence that the current tech-
nique would have on the results of this study. RA may be the 
only alternative to surgery for lesions that are resistant to high 
balloon pressures or when balloon delivery is not possible 
due to severe CAC. The introduction of the RotaLink system 
with interchangeable burrs leads to a considerable reduction 
in costs compared to inseparably linked disposable devices 
with one burr size. Further studies are necessary to clarify the 
role of RA combined with stents.
In the current study, we noticed that the high-risk group 
assessed by EuroSCOREs and shorter stent(s) deployed after 
RA were significantly associated with the incidence of MACCE, 
but not MACE. 
Limitations of the study
The primary limitations of the present study are the small 
cohort of patients, the lack of randomisation, and the lack 
of a CABG arm. The overall number of events was low, thus 
the results from Cox regression analyses should be considered 
rather exploratory and hypothesis-generating.
CONCLUSIONS
In conclusion, RA is a safe and sufficient technique for endo-
vascular treatment of severe CCALs, and in the hands of an 
expert, it may maintain its advantage over routine angioplasty 
with DES implantation even in high-volume centres with a low 
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rate of RA procedures. Future long-term outcome studies are 
needed to evaluate the optimal technique for RA use, to de-
termine whether routine use of RA before current-generation 
DES improves outcomes in high-risk patients with CAC, and 
whether those results are better than those seen in patients 
treated with cardiac surgery. Interventional cardiologists in 
high-volume centres should be familiar with RA and apply it 
more frequently in this specific group of patients. 
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Długoterminowe wyniki zastosowania  
aterektomii rotacyjnej u chorych z silnie  
uwapnionymi zmianami miażdżycowymi  
w tętnicach wieńcowych:  
doświadczenia jednego ośrodka
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S t r e s z c z e n i e
Wstęp: Aterektomia rotacyjna (AR) odgrywa ważną rolę w dobie szerokiego dostępu do zabiegów przezskórnych interwencji 
sercowo-naczyniowych (CV), szczególnie w erze starzenia się populacji i ekspansji wskazań do poszczególnych metod przezskór-
nych zabiegów w obrębie tętnic wieńcowych. Ograniczenia dla klasycznych przezskórnych interwencji wieńcowych z implantacją 
stentu uwarunkowane silnym uwapnieniem tętnic wieńcowych, często występujące u chorych w podeszłym wieku, obciążonych 
dużym operacyjnym ryzykiem CV, mają kluczowe znaczenie w powiększającej się grupie pacjentów poddawanych zabiegom RA.
Cel: W niniejszym badaniu retrospektywnym oceniono częstość powikłań okołozabiegowych i długoterminowe efekty za-
stosowania AR. Dodatkowo przeanalizowano związek potencjalnych czynników ryzyka RA, które mogą wpływać na częstość 
występowania głównych incydentów sercowo-naczyniowych (MACE) oraz sercowo-naczyniowych i mózgowych (MACCE) 
w długoterminowym okresie obserwacyjnym. 
Metody: Badaniem objęto 60 kolejnych chorych poddanych AR między styczniem 2002 r. i majem 2016 r. Maksymalny 
okres obserwacji wynosił 2616 dni dla MACE (zgon, zawał serca i ponowna rewaskularyzacja naczynia docelowego) oraz 
MACCE (MACE i udar mózgu).
Wyniki: Średni wiek pacjentów objętych badaniem wynosił 72,1 roku; mężczyźni stanowili 78,3% wszystkich chorych obję-
tych badaniem. Średni odsetek EuroSCORE II wyniósł 6,5%, natomiast SYNTAX score 24,1 pkt. Średni okres obserwacji trwał 
835,3 ± 611,8 dnia. Wszyscy chorzy przebyli skuteczny zabieg AR, a powikłania pozabiegowe wystąpiły u 12 (20%) osób 
i były to m.in.: wstrząs kardiogenny u 3 chorych (z których 2 pacjentów zmarło), rozwarstwienie tętnicy wieńcowej u 1 cho-
rego, okołoabiegowy zawał serca u 2 chorych, a także krwiak związany z dostępem naczyniowym wymagający przetoczenia 
koncentratu krwinek czerwonych, przerwanie ciągłości prowadnika, nadkomorowe tachykardia leczona parenteralnymi lekami 
antyarytmicznymi, perforacja tętnicy udowej powikłana krwiakiem pozaotrzewnowym wymagająca zaopatrzenia chirurgicznego, 
nefropatia kontrastowa oraz zwolniony przepływ kontrast w tętnicy poddawanej zabiegowi AR, odpowiednio, u 1 pacjenta. 
W okresie obserwacyjnym, który maksymalnie wyniósł 2616 dni, 64% chorych było wolnych od MACCE, natomiast 68% od 
MACE. Analiza jednoczynnikowa Coxa wykazała większą częstość występowania MACCE w grupie osób z większym ryzy-
kiem CV oszacowanym za pomocą skali EuroSCORE II przed zabiegiem oraz z większą długością implantowanych stentów. 
W przypadku MACE taki związek wykazano jedynie dla odsetka EuroSCORE II. W analizie wieloczynnikowej metodą Coxa, 
zarówno średnia długość stentu, jak i EuroSCORE II były niezależnymi czynnikami ryzyka wystąpienia MACCE w grupie cho-
rych po RA, natomiast w przypadku MACE niezależnym czynnikiem okazał się tylko EuroSCORE II. 
Wnioski: Aterektomia rotacyjna jest bezpieczną i skuteczną metodą leczenia wewnątrznaczyniowego w grupie chorych 
z masywnymi zwapnieniami w tętnicach wieńcowych. W badanej populacji pacjentów po kolejnych zabiegach AR przepro-
wadzonych w ciągu kilkunastu lat, wykonanych w jednym ośrodku, większe ryzyko CV w skali EuroSCORE II przed zabiegiem 
AR oraz większa średnia długość implantowanych stentów po zabiegu AR okazały się czynnikami ryzyka związanymi z większą 
częstością wystąpienia MACE i MACCE w długookresowej obserwacji.
Słowa kluczowe: aterektomia rotacyjna, komplikacje, skuteczność, główne incydenty sercowo-naczyniowe oraz mózgowe
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